TNGX · Tango Therapeutics, Inc.

The thesis

Tango Therapeutics' ESMO update on 23 October 2026 put the response rate for vopimetostat plus Revolution Medicines' daraxonrasib in pancreatic cancer at 82% in 22 evaluable patients, down from 92% in 12 patients in June. The shares fell on the day, and the next facts that settle the case are the first-half 2027 Phase 3 start and the third-quarter report. The rating stays low because the larger dataset confirmed an active combination but did not extend the June number.

The narrative is maturing: the data are now public in full, and the shares closed at $22.20 on 26 October 2026, against a $27.93 close on 22 October 2026 reported by IBTimes. The European Society for Medical Oncology (ESMO) data show 18 of 22 patients responded, every patient had disease control, and 88% were alive and progression-free at nine months, with median progression-free survival (PFS) not reached (pharmaphorum and IBTimes, 23 October 2026). The data cutoff was 20 August 2026, per IBTimes.

The shares had risen about 28% from $21.89 on 13 October 2026 into the report, according to IBTimes, so most of the move up reversed within one session. The $22.00 invalidation level in the previous note sits 0.9% below the latest close.

Bullish and bearish views on Tango Therapeutics, Inc.

The bull case on Tango Therapeutics, Inc. (TNGX), in brief: The combination remains highly active. The bear case: The headline response rate fell.

Bull case

• The combination remains highly active. At ESMO, 18 of 22 evaluable patients with MTAP-deleted, RAS-mutant pancreatic cancer responded, and 88% were progression-free at nine months (pharmaphorum, 23 October 2026). Median PFS has not been reached.
• A dated Phase 3 path now exists. Tango plans a global randomized trial of vopimetostat 200 mg plus daraxonrasib against standard chemotherapy as front-line treatment, starting in the first half of 2027 after FDA discussions (pharmaphorum and IBTimes, 23 October 2026). The Q2 release of 11 August 2026 had given no start date.

• Sell-side support continues. H.C. Wainwright's target is $68 (18 August 2026), and a Investing.com summary dated 22 September 2026 listed Guggenheim at $35, Mizuho and Stifel at $40 and JPMorgan at $46. William Blair initiated coverage with an Outperform rating on 16 October 2026.

Bear case

• The headline response rate fell. The 82% rate in 22 patients compares with 92% in 12 patients in June. Pharmaphorum did not report confirmed responses, and the June figure included 9 confirmed of 11.
• Dose tolerability is narrow. The 200 mg once-daily dose was generally well tolerated in 30 patients, while the 250 mg dose was not (pharmaphorum, 23 October 2026). Phase 3 therefore rests on one dose level.
• Stock supply is available at any time. A prospectus supplement filed 11 August 2026 allows up to $400 million of at-the-market stock sales without notice. Shares outstanding rose from 144,647,982 before the June 2026 offering to 168,380,091 in the Q2 10-Q.
• Insiders sold into strength. Principal accounting officer Jessica Newcomb sold 8,200 shares at weighted averages of $22.80 to $25.17 under a 10b5-1 plan (Form 4, 22 September 2026). IBTimes also reported a company affiliate filing to sell up to 15,231 shares around the ESMO date.
• The partner controls the key drug. Revolution Medicines owns daraxonrasib, its supply and its registrational trials. Daraxonrasib is also active alone, so the combination data do not isolate vopimetostat's contribution.

Price setup

The shares closed at $22.20 on 26 October 2026 (adjusted daily closes). That is 32.5% below the 52-week closing high of $32.90 and 14.1% below the close three months earlier. The 14-day relative strength index is 50.9.

IBTimes reported an early move on 23 October 2026 of about 16% lower to $23.40, on volume above 3.8 million shares. The shares then closed the following session near the 13 October 2026 level.

The previous note's range floor of $22.00, the low end of late-September trading, is the nearest observable support. A close below it would put the shares under the full run-up that preceded the data.

Catalysts, next 30 days

• ~10 November 2026, est.: Third-quarter 2026 results and 10-Q. The filing will disclose any at-the-market sales and may update the Phase 3 design and timing.
• First half 2027: Planned start of the front-line Phase 3 trial, a later event but the one the case turns on.

Elapsed catalysts

• 27 October 2026: ESMO closes. Presentation of the expanded dataset is complete; further commentary or analyst target revisions are likely to follow. (passed 10d ago)

What would change the view

The case breaks if the Phase 3 start slips beyond first-half 2027, if confirmed response rates in the 22-patient dataset prove materially lower than the reported 82%, or if the 200 mg dose shows tolerability problems in a larger group. The price condition is a daily close below $22.00, the low end of late-September trading.

A rating increase would need a confirmed-response figure at or near the June level, a dated trial start from Tango, or at-the-market proceeds disclosed at prices that did not weigh on the shares.

What it trades with

Tango's valuation moves with Revolution Medicines' progress on daraxonrasib, including its FDA review in previously treated pancreatic cancer. The shares also trade with small- and mid-cap oncology and the broader biotech group, and equity-raising windows in that group affect supply around data.